The Impact of a Follow-up Nursing Consultation in Lung Cancer Patients Receiving Immunotherapy
DOI:
https://doi.org/10.82582/thorac.17Keywords:
Immune Checkpoint Inhibitors, Immunotherapy/adverse effects, Lung Neoplasms/drug therapy, Lung Neoplasms/nursing, Referral and ConsultationAbstract
The use of immune checkpoint inhibition (ICI) has revolutionized cancer treatment. However, these medications are associated with significant and potentially debilitating immunerelated adverse events or even life-threatening. It is important for the health team, and particularly the nurse team, to recognize and manage toxicities early in order to limit severe toxicity and to enhance the patient’s quality of life. The goal was to identify health gains from implementing a nursing consultation to patients with lung cancer treated with checkpoint inhibitors.
Observational, longitudinal, prospective and exploratory study initiated November 1st, 2019, until December 31st, 2020, at the Portuguese Cancer Institute (IPOLFG) in Lisbon.
This study included 41 men and 23 women, ranging from 31 to 90 years old (averaging 63 years of age) and ECOG PS: 1.
A total of 32.8% of patients experienced at least one adverse event (AE). Of the reported adverse events, 29.7% occurred with pembrolizumab administration and 52.9% with nivolumab. The average of the AE showing up, happens after C2.
The study shows the nurses’ critical need and role for appropriately engaging with, educating, assessing and managing lung cancer patients under immunotherapy. All patients benefited from the creation of this consultation. Even patients who did not experience adverse events reported a need for advice from the nursing team.
Downloads
References
Parente B, Barata FJ, Neto IG. Cancro do pulmão — O doente terminal. Rev Port Pneumol. 2002;8:351-72;
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50. J Clin Oncol. 2021;39:2339-49. doi: 10.1200/JCO.21.00174;
Berghmans T, Dingemans AM, Hendriks LE, Cadranel J. Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm. Eur Respir J. 2020;55:1901907. doi: 10.1183/13993003.01907-2019;
Lim SM, Hong MH, Kim HR. Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Netw. 2020;20:e10. doi: 10.4110/in.2020.20.e10;
Martinez P, Peters S, Stammers T, Soria JC. Immunotherapy for the First-Line Treatment of Patients with Metastatic Non- Small Cell Lung Cancer. Clin Cancer Res. 2019;25:2691-8. doi: 10.1158/1078-0432.CCR-18-3904;
Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559-74. doi: 10.1093/annonc/mdv623;
Kennedy LB, Salama AK. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70:86-104. doi: 10.3322/ caac.21596;
Brahmer JR, Lacchetti C, Thompson JA. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2018;14:247-9. doi: 10.1200/JOP.18.00005;
Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW, et al. Immune-Related Adverse Events Associated with Anti-PD-1/ PD-L1 Treatment for Malignancies: A Meta-Analysis. Front Pharmacol. 2017;8:730. doi: 10.3389/fphar.2017.00730;
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-68. doi: 10.1200/ JCO.2017.77.6385;
Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and followup. Ann Oncol. 2022;33:1217-38. doi: 10.1016/j.annonc.2022.10.001;
European Oncology Nursing Society. EONS Cancer Nursing Education Framework. Brussels: EONS; 2018;
Tomey A, Alligood M. Teóricas de Enfermagem e a sua obra, modelos e teorias de enfermagem. Loures: Lusodidact; 2004;
Henderson V. Princípios básicos de enfermagem da CIE. Loures:Lusodidacta; 2007;
McIlfatrick S, Sullivan K, McKenna H, Parahoo K. Patients’ experiences of having chemotherapy in a day hospital setting. J Adv Nurs. 2007;59:264-73. doi: 10.1111/j.1365-2648.2007.04324.x;
Zhai X, Zhang J, Tian Y, Li J, Jing W, Guo H, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Cancer Biol Med. 2020;17:599-611. doi: 10.20892/j.issn.2095-3941.2020.0102;
Burke M, Rashdan S. Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. Front Oncol. 2021;11:720759. doi: 10.3389/fonc.2021.720759;
Leighl NB, Hellmann MD, Hui R, Carcereny E, Felip E, Ahn MJ, et al. Pembrolizumab in patients with advanced non-smallcell lung cancer (KEYNOTE-001): 3-year results from an openlabel, phase 1 study. Lancet Respir Med. 2019;7:347-57. doi: 10.1016/S2213-2600(18)30500-9.
Downloads
Published
Data Availability Statement
The data from the article was made in Excel exclusively by the authors.
Issue
Section
License
Copyright (c) 2026 Author(s) (or their employer(s)) and THORAC 2024
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
